Tamiflu News and Research

RSS

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

ABI provides clinical update on company activities

Amarillo Biosciences, Inc. (ABI) today provided an update on company activities.

15 Oct 2011

Microbiologist offers advice to guard against coming down with the flu

October marks the beginning of flu season, and once again, health care professionals are exhorting people to get a flu shot. Microbiologist John Tudor, Ph.D., professor of biology at Saint Joseph's University in Philadelphia, agrees that it's time to roll up our sleeves and offer up our arms for the vaccination.

28 Sep 2011

Something like 'Contagion' could happen for influenza

In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.

15 Sep 2011

Tamiflu resistant flu found in Newcastle, Australia

The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.

2 Sep 2011

Gold nanoparticles for rapid, accurate diagnosis of flu

Arriving at a rapid and accurate diagnosis is critical during flu outbreaks, but until now, physicians and public health officials have had to choose between a highly accurate yet time-consuming test or a rapid but error-prone test.

4 Aug 2011

Universal flu vaccine with super antibodies in near future

Researchers are close to developing a “super antibody” against flu that could be used as a universal treatment and pave the way for the development of a universal vaccine against the disease that affects billions of people every year.

29 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

New Tamiflu anti-viral flu medication in lower concentration

When flu season arrives this fall, a liquid form of Tamiflu—the most widely used anti-viral flu medication—will be available in a new, lower concentration to reduce the possibility of medication errors.

14 Jul 2011

New swine flu variant shows some resistance to drugs, report says

A new variant of H1N1 (swine) influenza that is easily spread and retains some resistance to the two major drugs used to treat flu has been detected in Singapore and Australia, according to a report from the WHO's influenza research group published in the journal Eurosurveillance, Bloomberg reports.

13 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

Flu cases rise by 50% in Queensland: Residents alerted

According latest reports, flu cases in Queensland have increased by more than half since last year, causing concern among doctors about an early on-set of flu season. The Australian Medical Association Queensland has revealed close to 1600 cases of flu have been reported across the state this year, with as many as 460 cases reported over the last five weeks alone. They add that that as many as 30 per cent of the flu cases reported were the H1N1 virus, more commonly known as swine flu.

2 Jun 2011

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection.

3 May 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

After many years of gradual increase followed by a three-year levelling off period, sales of addictive anxiolytic and hypnotic drugs decreased by just under two per cent in 2010.

24 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

Cancer drug may help combat flu

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.

1 Mar 2011

Natco Pharma files ANDA with FDA for generic version of Tamiflu

Alvogen, the US-based pharmaceutical company, today announced that its India-based partner, Natco Pharma Limited, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the generic version of Tamiflu.

9 Feb 2011